a Sanofi company, announced today that new longer-term data on its
relapsing multiple sclerosis treatments, Aubagio®
(teriflunomide) and Lemtrada® (alemtuzumab), will be
featured during the 67th annual meeting of the American
Academy of Neurology (AAN) being held in Washington, D.C. April 18-25.
The company will present 30 platform and poster presentations from its
MS franchise, including 19 on Lemtrada, 10 on Aubagio and one pipeline
presentation. Key data being presented at AAN include: